Skip to content
BOLUS

Signal from the log

Unnatural Products

45 M$ · Series B · United States · Biotech

Biotech de Santa Cruz qui développe des peptides macrocycliques de synthèse, des molécules assez sélectives pour viser les interactions entre protéines à l'intérieur de la cellule, que les médicaments classiques n'atteignent pas. Elle cible les maladies cardiovasculaires, métaboliques, inflammatoires et les fibroses. Le tour suit un accord avec Novartis pouvant atteindre 1,7 milliard de dollars en paiements d'étape.

Verified

Announced on , logged by the watch of 12 August 2026.

Operation
Funding round
Announced amount
45 M$
Stage
Series B
Country
United States
Sector
Biotech

What the log says

Editorial note, in French

Communiqué ouvert, montant relu et fonds nommés.

The investors

Led by The Venture Collective , with Merck Global Health Innovation Fund , Artis Ventures , First Spark Ventures , Droia Ventures

Provenance
Source longevity
Logged on 12 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.

One address, nothing else.

One letter a week, on Fridays: the week's funding rounds, the funds named, the amounts double checked. The list is never sold, one click to unsubscribe. The letter is written in French.

Email confirmation before any subscription. The list is never sold. What Bolus knows about you is written on the privacy page (in French).